Literature DB >> 9118855

Rasmussen's syndrome: longitudinal EEG study from the first seizure to epilepsia partialis continua.

G Capovilla1, F Paladin, B D Bernardina.   

Abstract

PURPOSE: The aim of our work was to describe the initial electroencephalographic characteristics of Rasmussen's syndrome (RS).
METHODS: We performed repeated EEG recordings in an 11-year 5-month-old girl affected by RS, as demonstrated through the progressive evolution of the illness. All EEGs were carried out in polygraphy and videorecordered, both in waking and in sleep.
RESULTS: In our opinion, our patient's EEG picture is absolutely unusual in childhood partial epilepsy form without any neuroradiologic perturbation. Delta focal activity persistence in such a clinical context should be considered an RS sign, among the possible causes.
CONCLUSIONS: We are not aware of any early-stage RS EEG description. We think that the initial RS EEG picture is so unusual as to suggest such pathology. We hope that analogous reports can confirm our belief.

Entities:  

Mesh:

Year:  1997        PMID: 9118855     DOI: 10.1111/j.1528-1157.1997.tb01739.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Utility of Tc 99m HMPAO SPECT in the early diagnosis of Rasmussen's syndrome.

Authors:  F Paladin; G Capovilla; A Bonazza; R Mameli
Journal:  Ital J Neurol Sci       Date:  1998-08

2.  Serial MRI and MRS studies with unusual findings in Rasmussen's encephalitis.

Authors:  D Türkdogan-Sözüer; M M Ozek; A Sav; A Dinçer; M N Pamir
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

3.  Rasmussen encephalitis: long-term outcome after surgery.

Authors:  Vera C Terra-Bustamante; Helio R Machado; Ricardo dos Santos Oliveira; Luciano N Serafini; Cecília Souza-Oliveira; Sara Escorsi-Rosset; Elza Márcia Targas Yacubian; Maria da Graça Naffah-Mazzacoratti; Carla A Scorza; Esper A Cavalheiro; Fulvio A Scorza; Américo C Sakamoto
Journal:  Childs Nerv Syst       Date:  2009-01-20       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.